Skip to main content
. 2020 Oct 10;24:100826. doi: 10.1016/j.bbrep.2020.100826

Fig. 1.

Fig. 1

Flow cytometry against cancer cells and normal cells using anti-PODXL mAbs (PcMab-47 and PcMab-60). LN229 (A), LN229/PODXL (B), MIA PaCa-2 (C), VEC-1 (D), and VEC-2 (E) cells were treated with PcMab-47 (10 μg/mL), PcMab-60 (10 μg/mL), or control, followed by secondary antibodies. Vascular endothelial cells, VEC.